Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions

Journal of Clinical Psychopharmacology

Volumn 29, Issue 2, 2009, Pages 109-116

  Birkenaes, Astrid B ^a,b,e   Birkeland, Kåre I ^c   Friis, Vein ^a,d   Opjordsmoen, Stein ^a,d   Andreassen, Ole A ^a,d  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e Department of Psychiatry A hus ^*  (Norway)

Author keywords

Adiponectin; Antipsychotics; Cortisol; Insulin; Leptin; SHBG

Indexed keywords

ADIPONECTIN; AMISULPRIDE; ARIPIPRAZOLE; CHLORPROTHIXENE; FLUPENTIXOL; GLUCOSE; HYDROCORTISONE; INSULIN; LEPTIN; LEVOMEPROMAZINE; LIPID; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SEX HORMONE BINDING GLOBULIN; ZIPRASIDONE; ZUCLOPENTHIXOL;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD LEVEL; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; ETHNIC DIFFERENCE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL PATIENT; METABOLIC DISORDER; METABOLIC PARAMETERS; MONOTHERAPY; OUTPATIENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION;

ADIPONECTIN; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CONTROLLED CLINICAL TRIALS AS TOPIC; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROCORTISONE; INSULIN; LEPTIN; MALE; MENTAL DISORDERS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SEX HORMONE-BINDING GLOBULIN; YOUNG ADULT;

EID: 67649348184     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31819b95fc     Document Type: Article

References (53)

1. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62:22-31.
2. American Diabetes Association. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
3. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr. 2006;11:32-39.
4. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54:862-871.
5. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry. 2002;47:742-749.
6. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289-297.
7. Jin H, Meyer JM, Mudaliar S, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin and adiponectin. Schizophr Res. 2008;100:70-85.
8. 1 receptor-linked activation of hypothalamus AMP-kinase. Proc Natl Acad Sci U S A. 2007; 104:3456-3459.
9. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519-526.
10. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1-17.
11. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1-95.
12. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004;50:1511-1525.
13. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponectin - a key adipokine in the metabolic syndrome. Diabetes Obes Metab. 2006;8:264-280.
14. Birkeland KI, Hanssen KF, Torjesen PA, et al. Level of sex hormone-binding globulin is positively correlated with insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 1993;76:275-278.
15. Cikim AS, Ozbey N, Sencer E, et al. Associations among sex hormone binding globulin concentrations and characteristics of the metabolic syndrome in obese women. Diabetes Nutr Metab. 2004; 17:290-295.
16. Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity. Int J Obes Relat Metab Disord. 2000;24:80-85.
17. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-454.
18. Newcomer JW, Selke G, Melson AK, et al. Dose-dependent cortisol-induced increases in plasma leptin concentrations in healthy humans. Arch Gen Psychiatry. 1998;55:995-1000.
19. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose and elevation of cortisol in drug-naive first-episode schizophrenia. Am J Psychiatry. 2003;160:284-289.
20. Haupt DW, Fahnestock PA, Flavin KA, et al. Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients. Neuropsychopharmacology. 2007;32:2561-2569.
21. Baptista T, Lacruz A, de Mendoza S, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry. 2000;33:81-88.
22. Baptista T, Lacruz A, Angeles F, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry. 2001;34:223-231.
23. Baptista T, Dávila A, El Fakih Y, et al. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol. 2007;22:205-211.
24. Graham KA, Perkins DO, Edwards LJ, et al. Effect of OLZ on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry. 2005;162:118-123.
25. Haupt DW, Luber A, Maeda J, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology. 2005;30:184-191.
26. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62:19-28.
27. Hägg S, Soderberg S, Ahren B, et al. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry. 2001;62:843-848.
28. Melkersson KI, Hulting AL. Insulin and leptin levels in patients with schizophrenia or related psychoses - a comparison between different antipsychotic agents. Psychopharmacology. 2001;154:205-212.
29. Mei Bai Y, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68:1834-1839.
30. Richards AA, Hickman IJ, Wang AY, et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol. 2006;26:232-237.
31. Tanaka K, Morinobu S, Ichimura M, et al. Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1527-1532.
32. Scheepers FE, Gespen de Wied CC, Kahn RS. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. J Clin Psychopharmacol. 2001;21:575-582.
33. Jakovljevic M, Pivac N, Mihaljevic-Peles A, et al. The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:399-402.
34. Cohrs S, Röher C, Jordan W, et al. The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects. Psychopharmacology. 2006;185:11-18.
35. Baptista T, Sandia I, Lacruz A, et al. Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin. Int Clin Psychopharmacol. 2007;22:69-76.
36. Baptista T, Martínez J, Lacruz A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial. Can J Psychiatry. 2006;51:192-196.
37. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenia patients. Lancet. 1989;333:495.
38. Birkenaes AB, Opjordsmoen S, Brunborg C, et al. The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia. A comparative study. J Clin Psychiatry. 2007; 68:917-923.
39. De Leon J, Susce MT, Johnson M, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92:95-102.
40. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I DisordersYPatient Edition (SCID I/P, version 2.0). New York, NY: New York State Psychiatric Institute, Biometrics Research Dept; 1995.
41. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophr Bull. 1987;13:261-276.
42. Janssen I, Heymsfield SB, Allison DB, et al. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75:683-688.
43. McLaughlin T, Abbasi F, Cheal K, et al. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139:802-809.
44. Mathews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-419.
45. Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic treated patients under real life conditions. J Clin Psychopharmacol. 2008;28:132-137.
46. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment in schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
47. Sacher J, Mossaheb N, Spindelegger C, et al. Effects of olanzapine and ziprazidone on glucose tolerance in healthy controls. Neuropsychopharmacology. 2008;33:1633-1641.
48. Lam TKT, Gutierrez-Juarez R, Pocai A, et al. Brain glucose metabolism controls the hepatic secretion of triglyceride-rich lipoproteins. Nat Med. 2007;13:171-180.
49. Obici S, Zhang BB, Karkanias G, et al. Hypothalamic insulin signalling is required for inhibition of glucose production. Nat Med. 2002;8:1376-1382.
50. Söderberg S, Olsson T, Eliasson M, et al. A strong association between biologically active testosterone and leptin in non-obese men and women is lost with increasing (central) obesity. Int J Obes. 2001; 25:98-105.
51. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569-574.
52. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science. 2005;307:375-379.
53. Raeder MB, Bjelland I, Vollset SE, et al. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry. 2006;67:1974-1981.